WOBURN, MA / ACCESSWIRE / May 6, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will report financial results for the three months ended March 29, 2024 on Wednesday, May 15, 2024. The results will be released after the market close on Wednesday, May 15 and the company will host a conference call on Thursday, May 16 at 10:00am Eastern Time.
Conference Call and Webcast Information
| Toll Free | 1-877-877-1275 |
| International | 1-412-858-5202 |
| Webcast | Webcast | Biofrontera Inc. First Quarter 2024 Financial Results and Business Update Conference Call (choruscall.com) |
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com.
Contacts:
Investor Relations
Andrew Barwicki
1-516-662-9461
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.87 |
| Daily Change: | 0.03 3.57 |
| Daily Volume: | 82,344 |
| Market Cap: | US$9.280M |
August 13, 2025 May 15, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
